Ribavirin, tigecycline, HMG-CoA reductase inhibitors, clioquinol and VPA all demonstrated robust activity against AML preclinically in vitro and in vivo with little success in clinical trials. This evidence concerns the gene HMGCR and acute myeloid leukemia.